CeladonPlc Profile Banner
Celadon Pharmaceuticals PLC Profile
Celadon Pharmaceuticals PLC

@CeladonPlc

Followers
449
Following
77
Media
219
Statuses
372

Celadon is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and supply of breakthrough cannabis-based medicines.

Joined March 2022
Don't wanna be here? Send us removal request.
@CeladonPlc
Celadon Pharmaceuticals PLC
1 year
In a significant development for medical cannabis in the UK, Celadon Pharmaceuticals Plc was proud to be featured on Sky News. Celadon has initiated the first MHRA and NHS REC approved trial of its kind, targeting 5,000 patients with chronic pain. This follows the legalisation of
4
4
10
@CeladonPlc
Celadon Pharmaceuticals PLC
4 months
Although nearly three-quarters of the Scottish public are misinformed about the legal status of medicinal cannabis, support for it in Scotland is higher than in most other parts of the United Kingdom. #CEL #Medical #Cannabis #CeladonPharmaceuticals.
Tweet card summary image
scotsman.com
New research provides insight into why Scotland is one of the UK’s strongest supporters of medical cannabis.
0
0
0
@CeladonPlc
Celadon Pharmaceuticals PLC
4 months
UK adults remain confused about the legal status and availability of medical cannabis, despite it being legalised in 2018, a new survey has revealed. #CEL #Medical #Cannabis #CeladonPharmaceuticals.
Tweet card summary image
cannabishealthnews.co.uk
New research highlights the confusion over legality of medical cannabis in the UK.
0
0
1
@CeladonPlc
Celadon Pharmaceuticals PLC
4 months
Celadon Pharmaceuticals Plc - Funding Update. #CEL #Medical #Cannabis
Tweet media one
0
0
0
@CeladonPlc
Celadon Pharmaceuticals PLC
4 months
Celadon Pharmaceuticals Plc would like to address a number of enquiries received from shareholders regarding the RNS announcement this morning (24th March 2025), in which the Company proposed to seek shareholder approval to delist from AIM. 𝟭. 𝗬𝗼𝘂𝗿 𝗦𝗵𝗮𝗿𝗲𝘀.
1
0
0
@CeladonPlc
Celadon Pharmaceuticals PLC
4 months
Celadon Pharmaceuticals Plc - Board Changes and De-Listing Proposal. #CEL #Medical #Cannabis
Tweet media one
2
1
1
@CeladonPlc
Celadon Pharmaceuticals PLC
5 months
Celadon continues to engage closely with all creditors and stakeholders to ensure sufficient liquidity through April 2025, with the new facility expected to support operations into Q3 2025. #CEL #Medical #Cannabis #CeladonPharmaceuticals
Tweet media one
0
0
0
@CeladonPlc
Celadon Pharmaceuticals PLC
5 months
Celadon Pharmaceuticals Plc - Funding Update. #CEL #Medical #Cannabis
Tweet media one
0
1
2
@CeladonPlc
Celadon Pharmaceuticals PLC
5 months
In 2024, the UK’s total medical cannabis flower imports more than doubled, rising from nearly 7 tonnes in 2023 to over 15 tonnes in 2024. For the year to date, the UK has imported just over 2 tonnes, nearly half of which was sourced from Spain. #CEL.
Tweet card summary image
businessofcannabis.com
New data acquired from the Home Office by Prohibition Partners and Business of Cannabis shows that since 2021, the UK has imported the bulk of its medical cannabis from Spain. 
0
1
2
@CeladonPlc
Celadon Pharmaceuticals PLC
5 months
A survey has revealed that 84% of UK doctors would be willing to prescribe medical cannabis to manage chronic pain if it were part of the NHS toolkit. The research, commissioned by medical cannabis clinic Alternaleaf, comes as experts warn that the number of chronic pain.
0
2
6
@CeladonPlc
Celadon Pharmaceuticals PLC
5 months
Record numbers of Scots are paying for medical cannabis as NHS waiting lists leave them struggling to get conventional treatment. An unprecedented 3,440 Scots now have private prescriptions for the drug – mostly patients suffering from common conditions such as depression,.
0
1
4
@CeladonPlc
Celadon Pharmaceuticals PLC
5 months
Celadon is one of the first UK companies to be awarded licences by UK regulators and MHRA to cultivate and manufacture high-THC medicinal cannabis. The company operates in a highly regulated environment and as such is committed to the following standards and licences:. Controlled
Tweet media one
0
1
2
@CeladonPlc
Celadon Pharmaceuticals PLC
5 months
Celadon’s primary focus is chronic pain – a large, unaddressed market (8 million adults in the UK, 50 million in the US, 100 million in Europe), with many problems with existing opioid treatments. #CEL #Medical #Cannabis #CeladonPharmaceuticals #Biotech #Healthcare #ChronicPain
Tweet media one
0
1
3
@CeladonPlc
Celadon Pharmaceuticals PLC
5 months
While NHS progress remains stagnant, private cannabis clinics such as Releaf, are seeing growing numbers of patients report positive effects of cannabis-based treatments for a wide range of conditions. #CEL #Medical #Cannabis #CeladonPharmaceuticals.
Tweet card summary image
cannabishealthnews.co.uk
UK medical cannabis clinic, Releaf, is investing in an ambitious new research programme to collect critical real-world evidence on the effects of medical cannabis treatments. Could it help bridge the...
1
1
4
@CeladonPlc
Celadon Pharmaceuticals PLC
5 months
The three year secured committed credit facility with a Swiss-based individual lender is in addition to the existing unsecured £7.0m committed credit facility. As part of entering into the Facility the Company obtained a waiver from the Existing Facility provider to prevent any
Tweet media one
0
0
2
@CeladonPlc
Celadon Pharmaceuticals PLC
5 months
"We are pleased to have secured funding through the Facility at such an important time in the Company's growth journey. This Facility will support the growth in our operations to meet the growing interest in Celadon's product. "The additional flexibility that this brings to the
Tweet media one
0
0
3
@CeladonPlc
Celadon Pharmaceuticals PLC
5 months
Celadon Pharmaceuticals Plc - New Committed Credit Facility. Celadon Pharmaceuticals Plc announces that it has entered into a £1.95 million, three year secured committed credit facility with a Swiss-based individual lender. #CEL #Medical #Cannabis
Tweet media one
0
2
5
@CeladonPlc
Celadon Pharmaceuticals PLC
5 months
Cannabis-based medicines have shown rapid growth internationally, with a growing evidence base for its role in treating a variety of conditions (e.g. epilepsy, multiple sclerosis, autism). Celadon’s primary focus is chronic pain – a large, unaddressed market (8 million adults in
Tweet media one
0
0
1
@CeladonPlc
Celadon Pharmaceuticals PLC
6 months
The mainstream media is well known for getting cannabis research wrong. Is sensationalism the reason NHS doctors are reluctant to accept the medical benefits of cannabis?. #CEL #Medical #Cannabis #CeladonPharmaceuticals #Innovation.
Tweet card summary image
leafie.co.uk
The mainstream media is well known for getting cannabis research wrong. Is sensationalism the reason NHS doctors are reluctant to accept the medical benefits of cannabis?
0
1
3
@CeladonPlc
Celadon Pharmaceuticals PLC
6 months
Revealed: Boom in private market for medical cannabis. Eligible patients finding it impossible to obtain medical supply through NHS despite 2018 legalisation. #CEL #Medical #Cannabis #CeladonPharmaceuticals #Innovation #Collaboration #Growth.
Tweet card summary image
telegraph.co.uk
Eligible patients finding it impossible to obtain medical supply through NHS despite 2018 legalisation
0
1
3
@CeladonPlc
Celadon Pharmaceuticals PLC
6 months
Celadon Pharmaceuticals Plc - Finance Update. Received final £103k from its £1.0m draw down request. Celadon has also received a £389k tax credit from a R&D claim. #CEL #Medical #Cannabis #CeladonPharmaceuticals #Innovation
Tweet media one
1
1
5